Literature DB >> 15921412

Hassallidin A, a glycosylated lipopeptide with antifungal activity from the cyanobacterium Hassallia sp.

Torsten Neuhof1, Peter Schmieder, Karina Preussel, Ralf Dieckmann, Huong Pham, Franz Bartl, Hans von Döhren.   

Abstract

Hassallidin A (1), a new antifungal glycosylated lipopeptide, was isolated from an epilithic cyanobacterium collected in Bellano, Italy, identified as Tolypothrix (basionym Hassallia) species. Chemical, mass spectrometric, and spectroscopic analyses, including one- and two-dimensional NMR, were performed to determine an esterified eight-residue cyclic peptide linked with a carbohydrate and a fatty acid residue. Chiral GC-MS analysis revealed the occurrence of the nonproteinogenic amino acids D-allo-Thr, D-Thr, D-Tyr, D-Gln, and dehydroaminobutyric acid (Dhb) within the peptide moiety. The additional components of hassallidin A could be identified as alpha,beta-dihydroxytetradecanoic acid (Dht) and mannose. This is the first report on a cyclic peptide of cyanobacterial origin that contains both a fatty acid and a carbohydrate moiety. Compound 1 exhibits antifungal activity against Aspergillus fumigatus and Candida albicans with MIC values of 4.8 microg/mL for both test organisms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15921412     DOI: 10.1021/np049671r

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  16 in total

Review 1.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

Review 2.  A comprehensive review of glycosylated bacterial natural products.

Authors:  Sherif I Elshahawi; Khaled A Shaaban; Madan K Kharel; Jon S Thorson
Journal:  Chem Soc Rev       Date:  2015-11-07       Impact factor: 54.564

3.  Antifungal activity improved by coproduction of cyclodextrins and anabaenolysins in Cyanobacteria.

Authors:  Tania K Shishido; Jouni Jokela; Clara-Theresia Kolehmainen; David P Fewer; Matti Wahlsten; Hao Wang; Leo Rouhiainen; Ermanno Rizzi; Gianluca De Bellis; Perttu Permi; Kaarina Sivonen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-16       Impact factor: 11.205

Review 4.  Chemodiversity in freshwater and terrestrial cyanobacteria - a source for drug discovery.

Authors:  George E Chlipala; Shunyan Mo; Jimmy Orjala
Journal:  Curr Drug Targets       Date:  2011-10       Impact factor: 3.465

5.  Isolation, structure elucidation, and synthesis of eudistomides A and B, lipopeptides from a Fijian ascidian Eudistoma sp.

Authors:  Emily L Whitson; Anokha S Ratnayake; Tim S Bugni; Mary Kay Harper; Chris M Ireland
Journal:  J Org Chem       Date:  2009-02-06       Impact factor: 4.354

6.  Hassallidins, antifungal glycolipopeptides, are widespread among cyanobacteria and are the end-product of a nonribosomal pathway.

Authors:  Johanna Vestola; Tania K Shishido; Jouni Jokela; David P Fewer; Olli Aitio; Perttu Permi; Matti Wahlsten; Hao Wang; Leo Rouhiainen; Kaarina Sivonen
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-17       Impact factor: 11.205

7.  Loihichelins A-F, a suite of amphiphilic siderophores produced by the marine bacterium Halomonas LOB-5.

Authors:  Vanessa V Homann; Moriah Sandy; J Andy Tincu; Alexis S Templeton; Bradley M Tebo; Alison Butler
Journal:  J Nat Prod       Date:  2009-05-22       Impact factor: 4.050

Review 8.  Marine pharmacology in 2005-6: Marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action.

Authors:  Alejandro M S Mayer; Abimael D Rodríguez; Roberto G S Berlinck; Mark T Hamann
Journal:  Biochim Biophys Acta       Date:  2009-03-19

9.  Anabaenolysins, novel cytolytic lipopeptides from benthic Anabaena cyanobacteria.

Authors:  Jouni Jokela; Linn Oftedal; Lars Herfindal; Perttu Permi; Matti Wahlsten; Stein Ove Døskeland; Kaarina Sivonen
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

10.  Antifungal compounds from cyanobacteria.

Authors:  Tânia K Shishido; Anu Humisto; Jouni Jokela; Liwei Liu; Matti Wahlsten; Anisha Tamrakar; David P Fewer; Perttu Permi; Ana P D Andreote; Marli F Fiore; Kaarina Sivonen
Journal:  Mar Drugs       Date:  2015-04-13       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.